HPV-Associated Head and Neck Cancer Drug in the Works
ADXS-HPV is currently being evaluated in a Phase 1/2 study in HPV-positive head and neck cancer in the United Kingdom and one will be initiated in the United States this year.
ADXS-HPV is an immunotherapy that is designed to target cells expressing the HPV gene E7. Expression of the E7 gene from high-risk HPV variants is responsible for the transformation of infected cells into dysplastic and malignant tissues. Eliminating these cells can eliminate the dysplasia or malignancy.For more information call (609) 452-9813 or visit www.advaxis.com.